Laсtiale Uro in the prevention of postmenopausal urinary infection: LACMUS study results

Abstract

Background. The purpose was to assess the efficacy and safety of Lactiale Uro, a product containing two strains of Lactobacilli plus cranberry extract and vitamin A, in preventing recurrent urinary tract infections (UTIs) in postmenopausal women (LACMUS study). Materials and methods. This was a randomized, prospective, multicenter study. Subjects received Lactiale Uro twice daily for 26 weeks after recovery from UTI; the control group didn’t receive the product. The primary endpoint was the proportion of subjects with recurrent UTI episodes at the end of the study. Results. Seventy-seven women were screened; 65 were enrolled; 61 completed the study. After 26 weeks, a significantly lower number of women experienced recurrent UTIs with Lactiale Uro compared to no treatment (9.7 vs 23.3 %; P < 0.05). Lactiale Uro produced statistically significant improvements, such as lower rates of UTI episodes (12.9 vs 36.6 %; P < 0.05); longer time to first UTI episode (136 vs 27 days; P = 0.0038); shorter duration of active UTI episode (5 vs 11 days; P = 0.0199); and shorter duration of antibacterial therapy for an active UTI episode (4 vs 10 days; P = 0.0462). Conclusions. Lactiale Uro was safe and effective for the prevention of recurrent UTIs in postmenopausal women. These data require further well-designed trials to clarify possible benefits.